Reply to S. Sarosiek et al.
Christian Buske, Meletios A Dimopoulos, Pierre Morel
https://pubmed.ncbi.nlm.nih.gov/37348018/Actively Recruiting
Led by Christian Buske · Updated on 2026-05-05
80
Participants Needed
14
Research Sites
260 weeks
Total Duration
Researchers are investigating treatment options for Waldenstrf6ms macroglobulinemia WM, a condition where chemotherapy often results in low complete or very good partial response rates and limited duration of response. WM patients tend to be older and may not tolerate chemotherapy side effects well, so treatments without chemotherapy are especially appealing. Venetoclax, a drug approved for related blood cancers, has shown promising activity and low toxicity in WM patients, including those previously treated with Ibrutinib or with certain genetic mutations. Ibrutinib, while effective, requires continuous use and its success varies with genetic factors, limiting its adoption as a standard treatment. Fixed-duration treatment combining Venetoclax and Rituximab has shown deep responses in related diseases, suggesting it might improve outcomes for newly diagnosed WM patients. The study is an international, phase II, open-label, randomized trial comparing two treatment approaches for newly diagnosed WM patients needing therapy. One group receives a combination of Venetoclax and Rituximab, with Venetoclax dose gradually increased during the first 28-day cycle and continued for 12 cycles alongside Rituximab given intravenously monthly. The other group receives a combination of Dexamethasone, Rituximab, and Cyclophosphamide for six 28-day cycles. The study uses genetic markers MYD88 and CXCR4 to stratify patients before randomization. About 80 patients will participate across multiple sites. Participants will be monitored for treatment response and safety during and after therapy, with assessments including response rates at 12 and 24 months, progression-free survival over six years, and quality of life measured by questionnaires. Safety evaluations involve tracking adverse events, laboratory tests, heart monitoring, and vital signs over 12 months. The main goal is to see if Venetoclax plus Rituximab leads to better deep response rates compared to the standard chemotherapy combination. This trial aims to provide data supporting new treatment standards for WM.
CONDITIONS
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
D
Dajana Kaszynski, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Christian Buske
Lead Sponsor
Ludwig-Maximilians - University of Munich
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive either a combination of Venetoclax and Rituximab or a combination of Dexamethasone, Rituximab, and Cyclophosphamide according to their assigned treatment arm.
Monthly visits during treatment cycles
Duration - Up to 6 years
Participants are monitored for treatment response, safety, and long-term outcomes after the treatment period ends.
Periodic visits as scheduled for long-term monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Christian Buske, Meletios A Dimopoulos, Pierre Morel
https://pubmed.ncbi.nlm.nih.gov/37348018/Christian Buske
Lead Sponsor
Ludwig-Maximilians - University of Munich
Collaborating Sponsor